StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Somil Mehta, Sharekhan

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: 1 year18 Sept 2026via NDTV Profit

Entry₹1,194.9Inferred
Target₹1,300
Total upside +8.80% (call closed)
Stop lossNot given
Exit₹1,30026 Oct 2026, 12:19 pm
Target hit+8.80%0.00%upside left
Follow Somil Mehta for new calls(20% target hit, 15 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 20 active Long-term calls on DRREDDYSee 542 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 26 Oct 2026
15 supporting9 neutral13 opposing
Supports the BUY call (15)

Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside

NewsNdtv-Profit·26 Oct · today

(opens in new tab)

11 other SEBI-registered advisors have active long-term BUY calls on this stock, with 6 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 4d ago

(opens in new tab)

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 5d ago

(opens in new tab)

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · 5d ago

(opens in new tab)
Neutral / worth noting (9)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 2d ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 1w ago

(opens in new tab)
Weighs against the BUY call (13)

6 other SEBI-registered advisors have active long-term SELL calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 2d ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 2d ago

(opens in new tab)

Dr. Reddy's FTO-11 Facility Receives Two USFDA Form 483 Observations

NewsGoogle News·9 Oct · 2w ago

(opens in new tab)

A pre-approval inspection ends with USFDA observations at Dr. Reddy’s (RDY).

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Somil Mehta, Sharekhan

Every call and its outcome